FDA currently approves Janssen Covid-19 vaccine for emergency use authorization as a single primary vaccination dose for individuals 18 years of age and older and as a single booster dose for individuals 18 years of age and older at least two months after first dose.
Contraindications
- Allergy or Hypersensitivity
- Thrombosis with Thrombocytopenia
Precautions and Warnings
- Allergy or Hypersensitivity
- Thrombosis with Thrombocytopenia
- Immune thrombocytopenia
- Guillain-Barré Syndrome
- Altered immunocompetence
- Syncopy
- Limitation of vaccine effectiveness.